Comparative Pharmacology
Head-to-head clinical analysis: SEVELAMER HYDROCHLORIDE versus VELPHORO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEVELAMER HYDROCHLORIDE versus VELPHORO.
SEVELAMER HYDROCHLORIDE vs VELPHORO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sevelamer hydrochloride is a phosphate-binding polymer that binds dietary phosphate in the gastrointestinal tract, preventing its absorption and thereby reducing serum phosphate levels.
Iron-based phosphate binder that forms non-absorbable complexes with dietary phosphate in the gastrointestinal tract, reducing serum phosphate levels.
Initial dose: 800-1600 mg orally three times daily with meals. Titrate by 800 mg per meal at 2-week intervals based on serum phosphorus levels. Maintenance: typically 2.4-4.8 g/day divided with meals.
1-2 tablets (500-1000 mg iron) orally three times daily with meals; titrate to achieve serum phosphorus target.
None Documented
None Documented
Not applicable; sevelamer is not absorbed. The polymer acts locally in the gastrointestinal tract and does not have a measurable plasma half-life.
Not applicable (non-absorbed drug acting locally in GI tract; no systemic half-life).
Sevelamer hydrochloride is not absorbed systemically; it is eliminated entirely in the feces as the unchanged polymer. No renal or biliary elimination occurs.
Primarily fecal as unabsorbed drug; negligible renal excretion (<0.1%).
Category A/B
Category C
Phosphate Binder
Phosphate Binder